Coherus Oncology, Inc.
CHRS
$1.22
$0.065.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -31,632.44% | -302.24% | -120.85% | 111.98% | 99.79% |
| Total Depreciation and Amortization | -42.61% | -22.08% | 10.72% | 39.17% | 40.44% |
| Total Amortization of Deferred Charges | 72.79% | 72.79% | 72.79% | 72.79% | 200.88% |
| Total Other Non-Cash Items | 146.80% | 164.01% | 172.05% | -222.04% | -258.91% |
| Change in Net Operating Assets | 625.02% | -90.71% | 301.07% | 251.78% | 107.90% |
| Cash from Operations | 29.73% | -9.15% | 100.33% | 88.31% | 76.33% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -132.04% | -105.69% | -96.88% | 67.33% | 1,072.07% |
| Cash from Investing | -132.04% | -105.56% | -96.95% | 59.24% | 1,400.36% |
| Total Debt Issued | -100.00% | -100.38% | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -92.05% | -98.34% | -98.73% | -96.79% | -96.23% |
| Repurchase of Common Stock | 90.08% | 90.40% | -28.63% | 30.97% | 17.49% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -99.99% | -100.04% | 6,647.48% | 3,632.79% | 3,122.46% |
| Cash from Financing | 99.98% | 99.89% | -382.12% | -368.64% | -346.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -847.26% | -189.21% | -172.87% | -41.80% | 108.35% |